At the epigenomic level, DNA methylation–mediated silencing of tumor suppressors like RASSF1A correlates closely with YAP/TAZ hyperactivation, while non-coding RNAs (e.g., MIR100HG, GASS) modulate YAP’s nuclear import and transcriptional activity, offering candidate markers for resistance prediction and novel therapeutic targets (Tu et al., 2020; Sun and Chi, 2021). Here, YAP1 is linked to neoplasm.